博瑞医药：2025年净利润5605.64万元，同比减少70.37%

Core Viewpoint - The company reported a decline in total revenue and net profit for 2025, indicating challenges in the market and increased costs associated with R&D and depreciation [1] Financial Performance - Total revenue for 2025 was 1.224 billion, a decrease of 4.59% year-on-year [1] - Net profit for 2025 was 56.06 million, down 70.37% compared to the previous year [1] - Operating profit decreased by 89.90%, while total profit fell by 90.18% year-on-year [1] - Net profit attributable to the parent company decreased by 70.37%, and net profit after deducting non-recurring gains and losses dropped by 86.69% [1] - Basic earnings per share decreased by 71.11% compared to the same period last year [1] Contributing Factors - The decline in revenue and gross profit was attributed to changes in flu trends, competitive landscape, and fluctuations in customer demand [1] - Increased depreciation from completed construction projects contributed to higher costs [1] - The company also faced increased R&D expenses due to greater investment in innovative drugs [1]